InflaRx
Latest round
- Series D
Last raised
- Oct 2017
Total raised
- $30M
Investors
- 4
About InflaRx
InflaRx GmbH is a biopharmaceutical company focused on developing innovative treatments targeting inflammatory diseases by utilizing proprietary anti-C5a and C5a receptor inhibitors.InflaRx GmbH, founded in 2007 and headquartered in Jena, Germany, specializes in developing treatments for inflammatory diseases. The company has undergone strategic pivots and has been recognized for its focus on innovative biopharmaceutical solutions. Renfeng Guo is the founder of the company, while Niels Riedemann serves as the CEO. InflaRx GmbH develops proprietary anti-C5a and C5a receptor (C5aR) inhibitors aimed at treating life-threatening and debilitating inflammatory diseases.S. FDA for use in hospitalized adults with COVID-19, specifically for those requiring invasive mechanical ventilation or extracorporeal membrane oxygenation. This product targets the complement activation factor C5a, crucial in the inflammatory response.InflaRx generates revenue through the commercialization of its biopharmaceutical products, principally through sales of GOHIBIC to hospitals and healthcare systems under the FDA's Emergency Use Authorization. Revenue is derived from agreements with healthcare professionals and institutions, structured as direct sales to end-users, reflecting the urgency of need in treating severe inflammatory diseases.InflaRx plans to enhance its product offerings and expand into new markets. The company is focused on developing additional products targeting severe inflammatory conditions.”
Who invested in InflaRx
4 investors across 4 rounds
See all investors in InflaRx
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about InflaRx
Who invested in InflaRx?
InflaRx has 4 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has InflaRx raised?
InflaRx has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did InflaRx last raise money?
InflaRx's most recent round on record is a Series D, in Oct 2017.
What does InflaRx do?
InflaRx GmbH is a biopharmaceutical company focused on developing innovative treatments targeting inflammatory diseases by utilizing proprietary anti-C5a and C5a receptor inhibitors.
Where is InflaRx headquartered?
InflaRx is headquartered in Jena, Germany.
Which VCs invest in companies like InflaRx?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at InflaRx's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series D
Raising like InflaRx? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.